Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Biomedical stakeholders caution against limiting U.S.-China collaboration

A group of nearly 150 U.S. academics and biomedical research and drug development stakeholders warned that actions which create a climate of fear or limit international collaboration between U.S. and Chinese scientists could jeopardize U.S. leadership in biomedical science.

In a letter to

Read the full 426 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers